BigClassActions.com
Advertisement

Paul Halpern

Paul Halpern joined LawyersandSettlements.com in 2007 as a senior contributor. While the scope of his work covers a wide range of legal topics, his knack for getting to the heart of complex legal issues, along with his interest in victims' rights, have made for many compelling lawyer interviews.

  • Merck/Schering Tries to Wine and Dine Vytorin Back to Health
    Merck/Schering Tries to Wine and Dine Vytorin Back to Health
    March 24, 2008

    Kenilworth, NJ Since the results of the ENHANCE clinical tests for Merck/Schering-Plough's Vytorin combination anti-cholesterol drug were released in mid-January, sales of the drug have plunged as much as 17 percent. That's because the ENHANCE results showed that the $3-a-pill Vytorin, which combines Merck's Zetia with generic simvastatin, did no better than inexpensive simvastatin alone at lowering users' arterial plaque, and thus their risk for stroke or heart attack.

  • Zetia/Vytorin: "He was a good man and his life was cut short."
    Zetia/Vytorin: "He was a good man and his life was cut short."
    March 21, 2008

    Parachute, CO: Melissa Cruz's father was diagnosed with diabetes in 1996. That's why today she continues to wonder why in 2002 his doctor prescribed him Merck/Schering-Plough's Zocor, then added Zetia about a year later, and again in 2007—the same combination of anti-cholesterol drugs used in the companies' Vytorin.

  • Vytorin: "No one could tell me why I had a heart attack."
    Vytorin: "No one could tell me why I had a heart attack."
    March 18, 2008

    Dalton, GA Until a year ago, Larry Matthews had a normal life in this area near the Georgia-Tennessee border. He was physically active at home and at work, and like many men of a certain age, was keeping an eye on his cholesterol and blood pressure. That was before Vytorin, the combination Zetia/Zocor (simvastatin) anti-cholesterol drug from Merck/Schering-Plough, changed things for the worse.

  • Congressional Committee Investigating Bisphenol A as Hazardous to Infants
    Congressional Committee Investigating Bisphenol A as Hazardous to Infants
    January 19, 2008

    Washington, DC: The Chairman of the House Energy and Commerce Committee and the head of its Subcommittee on Oversight and Investigations are concerned about possible dangers to infants from bisphenol A. Michigan Democratic congressmen John Dingell and Bart Stupak want answers from the federal Food and Drug Administration (FDA) and seven companies that manufacture and package baby formula about the use and safety of bisphenol A in packaging that contains infant formula as well as in plastic nursing bottles.

Request Legal Help